News | February 09, 2023
JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
A pharma industry veteran with over three decades of experience in domestic as well as international markets
He is a Chartered Accountant with more than 19 years of extensive experience
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Krsnaa Diagnostics Limited has operationalized one diagnostics center at district hospital Male Akbarpur, Kanpur Dehat, Uttar Pradesh.
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Subscribe To Our Newsletter & Stay Updated
